Clinical trial
Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64…
NCT00464672 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00464672 |
|---|---|
| Title | Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old |
| Official title | A Phase III, Observer-Blind, Randomized, Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Immunogenicity of Two Trivalent Subunit Inactivated Influenza Vaccines in Healthy Children Aged 3 to 8 Years, in Healthy Children/Adolescents Aged 9 to 17 Years,and in Healthy Adults Aged 18… |
| Lead sponsor | Novartis, Industry |
| Collaborators | Novartis Vaccines Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological |
| Interventions | Influenza virus vaccine, Comparator influenza vaccine |
| Enrollment | 1,893 |
| Start date | Apr 1, 2007 |
| Primary completion | Jul 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Apr 24, 2007 |
| Last update posted | Oct 1, 2015 |
| Countries | Argentina |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: